Xtant Medical (XTNT) Projected to Announce Quarterly Earnings on Monday

Xtant Medical (NYSEAMERICAN:XTNT) is anticipated to release its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect the company to post earnings of ($0.02) per share and revenue of $24.8760 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:30 AM ET.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its quarterly earnings data on Wednesday, May 13th. The medical device company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02). The firm had revenue of $20.88 million during the quarter, compared to analysts’ expectations of $20.16 million. Xtant Medical had a return on equity of 3.68% and a net margin of 1.50%.

Xtant Medical Stock Down 0.6%

Shares of NYSEAMERICAN XTNT opened at $0.43 on Friday. The firm has a market capitalization of $60.28 million, a PE ratio of 43.02 and a beta of -0.16. The company has a current ratio of 3.34, a quick ratio of 1.64 and a debt-to-equity ratio of 0.17. Xtant Medical has a 1 year low of $0.39 and a 1 year high of $0.95. The firm’s 50-day moving average is $0.44 and its 200-day moving average is $0.52.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Nantahala Capital Management LLC raised its holdings in shares of Xtant Medical by 500.3% in the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock valued at $50,543,000 after purchasing an additional 57,000,000 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Xtant Medical by 4.6% during the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after purchasing an additional 104,159 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Xtant Medical by 28.8% during the fourth quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after purchasing an additional 205,945 shares during the last quarter. Mink Brook Asset Management LLC grew its position in Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after purchasing an additional 60,997 shares in the last quarter. Finally, Wiregrass Investment Management LLC bought a new position in Xtant Medical in the fourth quarter valued at $81,000. Institutional investors and hedge funds own 69.33% of the company’s stock.

Wall Street Analyst Weigh In

Separately, BTIG Research reissued a “buy” rating and set a $1.00 price target on shares of Xtant Medical in a research note on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $1.00.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.